How did YMAB's revenue and expenses shift in Q2 2024 compared to previous quarters?

Y-mAbs Therapeutics (YMAB) experienced a significant increase in revenue in Q2 2024, rising from $19.93 million in Q1 2024 to $22.8 million in Q2 2024. This indicates a strong financial performance during the period, which may be attributed to factors such as market conditions, business strategy, or operational efficiency improvements.

|code|Ticker|Name|Date|Total Revenue|Total Expenses|market_code|
|---|---|---|---|---|---|---|
|YMAB|YMAB.O|Y-mAbs Therapeutics|2023 Q3|2.0454E7||185|
|YMAB|YMAB.O|Y-mAbs Therapeutics|2023 Q4|2.3363E7||185|
|YMAB|YMAB.O|Y-mAbs Therapeutics|2024 Q1|1.9931E7||185|
|YMAB|YMAB.O|Y-mAbs Therapeutics|2024 Q2|2.2798E7||185|

|code|Ticker|Name|Date|Total Revenue|Total Expenses|market_code|
|---|---|---|---|---|---|---|
|YMAB|YMAB.O|Y-mAbs Therapeutics|2023 Q2|2.0751E7||185|
|YMAB|YMAB.O|Y-mAbs Therapeutics|2023 Q3|2.0454E7||185|
|YMAB|YMAB.O|Y-mAbs Therapeutics|2023 Q4|2.3363E7||185|
|YMAB|YMAB.O|Y-mAbs Therapeutics|2024 Q1|1.9931E7||185|